Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's Minister Of Health Calls For More Regional Support For Healthcare Reform

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's province leaders should increase their attention to healthcare investment, China's Minister Of Health Chen Zhu told reporters during the third session of the eleventh National People's Congress, the most influential meeting in China

You may also be interested in...



China's Pilot DRG Reimbursement Systems Indicate Substantial Changes To Hospital Prescription Habits

SHANGHAI - China is experimenting with pilot reimbursement programs that rely on diagnosis related groups (DRG) in cities across the country, looking for ways to reduce medical expenses

China's Pilot DRG Reimbursement Systems Indicate Substantial Changes To Hospital Prescription Habits

SHANGHAI - China is experimenting with pilot reimbursement programs that rely on diagnosis related groups (DRG) in cities across the country, looking for ways to reduce medical expenses

Tongjitang Pins Loss On Delayed Implementation Of China's Essential Drug List; Proposed Buyout Still Under Review

SHANGHAI - Tongjitang, the first traditional Chinese medicine company listed on the New York Stock Exchange, reported a $694,000 net loss during the second quarter for the year, attributing it to increased sales and marketing expenses for sales infrastructure and its essential drug sales network

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel